-- CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:
We keep our target at $1,225, 29.0x our 2027 EPS view, below LLY's five-year historical forward P/E average. We lift our 2026 EPS view to $36.97 from $34.71 and keep 2027's EPS at $42.22. LLY shares are up over 10% today after announcing a robust start to 2026, with Q1 revenue soaring 56% Y/Y to $19.8B, significantly beating our estimates and Street expectations. The strong performance was fueled by its incretin medicines, Mounjaro and Zepbound, which generated $12.8B combined. A key highlight of the Q1 earnings call was the FDA approval of Foundayo, the oral GLP-1 for weight management. We remain optimistic about Foundayo's potential to expand the obesity treatment market in the U.S. and overseas, given its convenience as a once-daily pill with no food or water restrictions. LLY is also demonstrating significant pipeline progress, including positive data for key assets such as Retatrutide, Jaypirca, and Ebglyss, plus four strategic acquisitions (Orna, Centessa, Kelonia, Ajax) to bolster its capabilities.